Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 39

Sort by

Sort Order Select

Journal Articles

Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study

Zhuoer Xie, MD, Ahmad Nanaa, Antoine Saliba, MD, Rong He, MD, Phuong L. Nguyen, MD, Dragan Jevremovic, MD PhD, Patricia Greipp, DO, Mohamed Salama, MD, Naseema Gangat, MBBS, Hassan B. Alkhateeb, MD, Ayalew Tefferi, MD, Mark Litzow, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD, Aref Al-Kali, MD

Blood (2020) 136 (Supplement 1): 44.

https://doi.org/10.1182/blood-2020-137527

Published: 2020

Journal Articles

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-134963

Published: 2020

Journal Articles

Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

Xavier A Andrade-Gonzalez, MD, Ayalew Tefferi, MD, Animesh Pardanani, MBBS, PhD, Naseema Gangat, MBBS, Mrinal M. Patnaik, MDMBBS, Jeanne M. Palmer, MD, Mohamed A. Kharfan-Dabaja, MDMBA, Mark Litzow, MD, Mithun Vinod Shah, MD PhD, William J Hogan, MB, BCh, Hassan B. Alkhateeb, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-141414

Published: 2020

Journal Articles

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Gordon Ruan, MD, Caleb J. Smith, MD, Courtney Day, William Harmsen, Abhishek A. Mangaonkar, MBBS, Hassan B. Alkhateeb, MD, Kebede H. Begna, MD, Aref Al-Kali, MD, Mark Litzow, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Animesh Pardanani, MBBS, PhD, Michelle A Elliott, MD, Ayalew Tefferi, MD, Ronald S. Go, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136350

Published: 2020

Journal Articles

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Hemant S. Murthy, MD, Kwang Woo Ahn, PhD, Noel Estrada-Merly, MS, Lohith Gowda, MD, Bhagirathbhai Dholaria, MBBS, Susan Bal, MDMBBS, Hassan B. Alkhateeb, MD, Deepa Jagadeesh, MDMPH, Betul Oran, MDMS, Ryotaro Nakamura, MD, Bart L. Scott, MD, Craig S. Sauter, MD, Francine M. Foss, MD, Mohamed A kharfan-Dabaja, MDMBA, Wael Saber, MD MS

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-134793

Published: 2020

Journal Articles

Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review

Aldo A. Acosta-Medina, MD, Ann M. Moyer, MDPhD, Ronald S. Go, MD, Maria Alice V. Willrich, PhD, Hassan B. Alkhateeb, MD, Christianne Bourlon De Los Rios, MDMSc, Dong Chen, MD, PhD, Fernando C. Fervenza, MDPhD, Nahla M. Heikal, MD, Nelson Leung, MD, Ariela L. Marshall, MD, Cheryl L. Tran, MD, Jeffrey L. Winters, MD, Meera Sridharan, MD PhD

Blood (2020) 136 (Supplement 1): 25–26.

https://doi.org/10.1182/blood-2020-136617

Published: 2020

Journal Articles

Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Ahmad Nanaa, Rama Nana, Zhuoer Xie, MD, Dragan Jevremovic, MD PhD, Phuong L. Nguyen, MD, Cynthia Hengel, Susan M. Geyer, PhD, Rong He, MD, David S. Viswanatha, MD, Michael M. Timm, Mohamed E Salama, MD, Min Shi, MDPhD, Patricia Greipp, DO, Hassan B. Alkhateeb, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Mrinal M. Patnaik, MDMBBS, Mithun Vinod Shah, MD PhD, Aref Al-Kali, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-142181

Published: 2020

Journal Articles

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Kalyan Nadiminti, M Hasib Sidiqi, MBBS, Kapil Meleveedu, MDMBBS, Hassan B. Alkhateeb, MD, Aref Al-Kali, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Shaji K. Kumar, MD, Mrinal M Patnaik, MDMBBS, Morie A. Gertz, MD, Dong Chen, MD PhD, Mithun Vinod Shah, MD PhD

Blood (2019) 134 (Supplement_1): 4560.

https://doi.org/10.1182/blood-2019-123065

Published: 2019

Journal Articles

Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias

Haya Azouz, Jessica Ternus, Phuong L. Nguyen, MD, Dragan Jevremovic, MD PhD, Mrinal M Patnaik, MDMBBS, Michael M. Timm, Min Shi, MD PhD, Rong He, MD, David S. Viswanatha, Mithun Vinod Shah, MD PhD, Hassan B. Alkhateeb, MD, Naseema Gangat, MBBS, Kebede H. Begna, MD, William J Hogan, MB, BCh, Mark Litzow, MD, Cindy Hengel, Aref Al-Kali, MD

Blood (2019) 134 (Supplement_1): 5406.

https://doi.org/10.1182/blood-2019-125114

Published: 2019

Journal Articles

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Meera Yogarajah, MD, Phuong L. Nguyen, MD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Kebede H. Begna, MD, Michelle A Elliott, MD, Naseema Gangat, MBBS, William J Hogan, MB, BCh, Ayalew Tefferi, MD, Mark Litzow, MD, Aref Al-Kali, MD

Blood (2019) 134 (Supplement_1): 5441.

https://doi.org/10.1182/blood-2019-125439

Published: 2019

Journal Articles

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Kalyan Nadiminti, Abhishek A Mangaonkar, MBBS, Kimberly J. Langer, D.N.P., C.N.P., Shakila P Khan, MD, Vilmarie Rodriguez, MD, Naseema Gangat, MBBS, Michelle A Elliott, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mark Litzow, MD, William J Hogan, MB, BCh, Saad S. Kenderian, MD, Mrinal M Patnaik, MDMBBS

Blood (2019) 134 (Supplement_1): 3300.

https://doi.org/10.1182/blood-2019-121742

Published: 2019

Journal Articles

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Blood (2019) 134 (Supplement_1): 4106.

https://doi.org/10.1182/blood-2019-127094

Published: 2019

Journal Articles

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Meera Yogarajah, MD, William J Hogan, MB, BCh, Naseema Gangat, MBBS, Dong Chen, MD PhD, Rong He, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, Mrinal M Patnaik, MDMBBS, Michelle A Elliott, MD, Mark Litzow, MD, Aref Al-Kali, MD, Animesh Pardanani, MBBS, PhD, Ayalew Tefferi, MD, Kebede H. Begna, MD

Blood (2019) 134 (Supplement_1): 3863.

https://doi.org/10.1182/blood-2019-125361

Published: 2019

Journal Articles

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

Zaid Abdel Rahman, MD, Michael G. Heckman, Kevin C. Miller, BS, Patricia Greipp, DO, Matthew R Spiegel, Sharad Khurana, MDMSc, Hassan B. Alkhateeb, MD, Mrinal M Patnaik, MDMBBS, Lisa Z. Sproat, MD, Liuyan Jiang, Vivek Roy, MD, Mark Litzow, MD, Mohamed A Kharfan-Dabaja, MDMBA, William J Hogan, MB, BCh, James M. Foran, MD

Blood (2019) 134 (Supplement_1): 2588.

https://doi.org/10.1182/blood-2019-122068

Published: 2019

Journal Articles

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Blood (2018) 132 (Supplement 1): 5440.

https://doi.org/10.1182/blood-2018-99-118600

Published: 2018

Journal Articles

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

Rajneesh Nath, MD, Zheng Zhou, MD PhD, Jan Cerny, MD PhD, Hai-Lin Wang, MPH, Khalid Bo-Subait, Zartash Guth, Gulrayz Ahmed, Muhammad Wagas Khan, Gerhard Carl Hildebrandt, MD, Hassan B. Alkhateeb, MD, Moussab Damlaj, MD, Mrinal M. Patnaik, MD MBBS, Brenda M. Sandmaier, MD, Daniel J. Weisdorf, MD, Marcos de Lima, MD, Mark R. Litzow, MD, Wael Saber, MD MS

Blood (2018) 132 (Supplement 1): 3456.

https://doi.org/10.1182/blood-2018-99-116795

Published: 2018

Journal Articles

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Aref Al-Kali, MD, Raoul Tibes, MD PhD, Jeanne Palmer, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MD MBBS, Kebede H. Begna, MD, Naseema Gangat, MBBS, Pamela Atherton, Shujun Liu, PhD, Rong He, MD, Shahrukh K. Hashmi, MD MPH, Mark R. Litzow, MD

Blood (2018) 132 (Supplement 1): 1443.

https://doi.org/10.1182/blood-2018-99-118552

Published: 2018

Journal Articles

Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System

Omar Alkharabsheh, MBBS, Mrinal M. Patnaik, MD MBBS, Naseema Gangat, MBBS, Kebede H. Begna, MD, Hassan B. Alkhateeb, MD, Mithun Vinod Shah, MD PhD, William J. Hogan, MBBCh, Rong He, MD, Patricia Greipp, DO, Phuong L. Nguyen, MD, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2018) 132 (Supplement 1): 5510.

https://doi.org/10.1182/blood-2018-99-113943

Published: 2018

Journal Articles

Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution Experience

Salwa S Saadeh, MBBS, Omar Alkharabsheh, MD, Darci Zblewski, CNP, Mrinal M. Patnaik, MDMBBS, Naseema Gangat, MBBS, Kebede H. Begna, MD, Hassan B. Alkhateeb, MD, Michelle A. Elliott, MD, Rong He, MD, Phuong Nguyen, MD, William J. Hogan, MBBCh, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 5310.

https://doi.org/10.1182/blood.V130.Suppl_1.5310.5310

Published: 2017

Journal Articles

Risk of Venous Thrombotic Events (VTE) in Patients with Myelodysplastic Syndromes with 5q Deletion during Lenalidomide Therapy: Single Institution Experience

Omar Alkharabsheh, MD, Darci Zblewski, CNP, Naseema Gangat, MBBS, Kebede H. Begna, MD, Michelle A. Elliott, MD, Hassan B. Alkhateeb, MD, Mrinal M. Patnaik, MDMBBS, William J. Hogan, MBBCh, Mark R. Litzow, MD, Aref Al-Kali, MD

Blood (2017) 130 (Supplement 1): 5315.

https://doi.org/10.1182/blood.V130.Suppl_1.5315.5315

Published: 2017

NARROW

Treatment Outcome for Symptomatic Patients with Clonal Cytopenia of Undetermined Significance: A Single-Institution Retrospective Study

Clinical, Molecular, and Prognostic Comparisons between Clonal Cytopenias of Undetermined Significance and Lower-Risk Myelodysplastic Syndromes - a Study of 184 Molecularly Annotated Patients

Pre- Transplant Ferritin Predicts Overall Survival and Non-Relapse Mortality in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis

A Population-Based Study of Chronic Myelomonocytic Leukemia in the United States from 2004-2015

Allogeneic Hematopoietic Cell Transplantation (allo-HCT) in T-Cell Prolymphocytic Leukemia (T-PLL): An Analysis from the CIBMTR

Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review

Predictors of Survival and Time to Progression to Myeloid Neoplasm in Patients with Clonal Cytopenias

Characteristics and Outcomes of Therapy Related Myeloid Neoplasms in Patients with Multiple Myeloma Following Autologous Stem Cell Transplantation

Correlation of Flow Cytometric Aberrations with Cytogenetic, Molecular Genetic, and Morphology in Patients with Unexplained Cytopenias

Discrepancy of Blast Percentage between the Bone Marrow Aspirate and Flow Cytometry and Its Impact on Survival Outcomes in Patients with Myelodysplastic Syndromes Excess Blast (MDS-EB)

Survival Outcomes Following Allogeneic Stem Cell Transplantation for Inherited Bone Marrow Failure and Myeloid Germline Predisposition Syndromes

Peak Lymphocyte Count after CAR T Infusion Is a Clinically Accessible Test That Correlates with Clinical Response in Axicabtagene Ciloleucel Therapy for Lymphoma

Acute Myeloid Leukemia with High Risk Features: Routine Central Nervous System Evaluation May be Beneficial

Impact of Targeted Immunotherapies and Novel Cytogenetic and Clinical Risk Groups on Outcome after Allogeneic Hematopoietic Stem Cell Transplant (AlloHCT) for Acute Lymphoblastic Leukemia (ALL): The Mayo Clinic Cohort

The Clinical Utility of Pharmacogenomics Testing in Assessing Tyrosine Kinase Inhibitor Therapy, Intolerance and Responses in Patients with Chronic Myelogenous Leukemia

Reduced Intensity Conditioning (RIC) Regimens Hematopoietic Cell Transplantation (HCT) for Acute Myeloid Leukemia (AML): A Comparison of Fludarabine/Busulfan (FB) and Fludarabine/Melphalan (FM) Based Regimens from the CIBMTR

A Phase II of Combination Daunorubicin and Cytarabine (Ara-C) and Nilotinib (TASIGNA) (DATA) in Patients Newly Diagnosed with Acute Myeloid Leukemia and KIT Expression: Final Results

Marrow Blast Percentage Impact on High-Grade Myelodysplastic Syndrome By the Revised International Prognostic Scoring System

Impact of Significant Eosinophilia in Patients with Myelodysplastic Syndromes: Single Institution Experience

Risk of Venous Thrombotic Events (VTE) in Patients with Myelodysplastic Syndromes with 5q Deletion during Lenalidomide Therapy: Single Institution Experience

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only